MIROCALS Consortium announces top-line results of European trial at 33rd International MND Symposium
The MIROCALS Trial Consortium - which includes scientists from the СŷÊÓƵ of Sheffield - have today announced the top-line results from the phase 2b trial of a low dose Interleukin-2 (ld IL2) in patients with Motor Neurone Disease.